Hydrogel microcapsules containing engineered bacteria for sustained production and release of protein drugs.
Biomaterials
; 287: 121619, 2022 08.
Article
em En
| MEDLINE
| ID: mdl-35700622
ABSTRACT
Subcutaneous administration of sustained-release formulations is a common strategy for protein drugs, which avoids first pass effect and has high bioavailability. However, conventional sustained-release strategies can only load a limited amount of drug, leading to insufficient durability. Herein, we developed microcapsules based on engineered bacteria for sustained release of protein drugs. Engineered bacteria were carried in microcapsules for subcutaneous administration, with a production-lysis circuit for sustained protein production and release. Administrated in diabetic rats, engineered bacteria microcapsules was observed to smoothly release Exendin-4 for 2 weeks and reduce blood glucose. In another example, by releasing subunit vaccines with bacterial microcomponents as vehicles, engineered bacterial microcapsules activated specific immunity in mice and achieved tumor prevention. The engineered bacteria microcapsules have potential to durably release protein drugs and show versatility on the size of drugs. It might be a promising design strategy for long-acting in situ drug factory.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hidrogéis
/
Diabetes Mellitus Experimental
Limite:
Animals
Idioma:
En
Revista:
Biomaterials
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China